4D Molecular Therapeutics Inc. 1.29% $218.19M ...

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes ...

After hours: January 30 at 4:01:12 PM EST Loading Chart for KRYS ...

Clearly, options traders are pricing in a big move for Krystal Biotech shares, but what is the fundamental picture for the company? Currently, Krystal Biotech is a Zacks Rank #4 (Hold) in the ...

Suma Krishnan, the President of R&D at Krystal Biotech , Inc. (NASDAQ:KRYS), has executed significant stock sales, according to a recent SEC filing. On December 13, Krishnan... Krish S. Krishnan ...

Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million.

Investing.com - Krystal Biotech (NASDAQ: KRYS) reported second quarter EPS of $-1.25, $0.02 better than the analyst estimate of $-1.27. Revenue for the quarter came in at $0.00 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...